BRAF and NRAS testing

BRAF and NRAS testing in melanoma

Signalling through the MAPK pathway leads to an increase in a number of cellular processes relevant to cancer survival. The NRAS and B-Raf proteins play a role in regulating this pathway and their disruption is implicated in the development and growth of malignant melanomas; activating mutations cause constitutive activation of the MAPK and PI3K/AKT pathways, leading to growth and progression of the tumour.

Approximately 40-60% of melanomas have mutations in the BRAF gene, a discovery which led to the development of targeted therapies such as Vemurafenib. This drug has been approved for treatment of patients with malignant melanoma with a V600E (c.1799T>A) mutation in the BRAF gene.

A further 20% of melanomas have a mutation in the NRAS gene, which is also a focus of drug development activity.

Contact us

NewGene Limited
Bioscience Building
International Centre for Life
Newcastle upon Tyne
NE1 4EP, UK

Tel: +44 (0)191 242 1923
Fax: +44 (0)191 241 8799
Email: info@newgene.org.uk

Click here for location map

Mon – Fri 08:30 to 17:00, closed Bank Holidays

An ISO 15189 accredited Medical Laboratory company

NewGene Limited | Company Number: 06735445

Technology Partners

Agilent Technologies

Agena Bioscience

Illumina

Sophia Genetics

Qiagen

Promega

Enquiry form